Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics plc

Yukselen Celik AS ( ($TR:YKSLN) ) just unveiled an update. Yükselen Çelik A.Ş. and its subsidiaries have released condensed consolidated interim fi...

Yükselen Çelik Publishes Limited-Reviewed Interim Financials for Mid-2026

Yukselen Celik AS ( ($TR:YKSLN) ) just unveiled an announcement. Yükselen Çelik Anonim Şirketi has released its interim activity report for the per...

Yükselen Çelik’s H1 2026 Activity Report Clears Limited Review

Yukselen Celik AS ( ($TR:YKSLN) ) has provided an update. Yukselen Celik AS announced that its consolidated financial statements for the period fro...

Yukselen Celik Affirms Compliance and Transparency in 2026 Interim Financial Reports

An update from Yukselen Celik AS ( ($TR:YKSLN) ) is now available. Yükselen Çelik AŞ reported first-half 2026 revenue of 838.8 million TL and EBITD...

Yükselen Çelik Returns to Profit in First Half of 2026 Despite Steel Market Headwinds

The latest update is out from Silence Therapeutics ( ($SLN) ). On August 11, 2026, Silence Therapeutics entered into an underwriting agreement with...

Silence Therapeutics Announces Major ADS Public Offering

An announcement from Stabilis Solutions ( ($SLNG) ) is now available. At Stabilis Solutions’ annual meeting held on August 10, 2026, stockholders e...

Stabilis Solutions Shareholders Reelect Board, Confirm Auditor

In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Silence Therapeutics, with a price target of $32.00. The...

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Silence Therapeutics (SLN), Hims & Hers Health (HI...

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jade Biosciences (JBIO), Silence Therapeutics (SLN) ...

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MoonLake Immunotherapeutics (MLTX) and Silence Thera...

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

The latest update is out from Basilea Pharmaceutica ( ($CH:BSLN) ). Basilea Pharmaceutica has secured an additional USD 5.4 million in non‑dilutive...

Basilea Wins More BARDA Funding for Novel Oral Antibiotic Targeting Drug‑Resistant UTIs

An update from Soluna Holdings ( ($SLNH) ) is now available. On July 30, 2026, Soluna Holdings, Inc. announced plans to release its second quarter ...

Soluna Holdings Schedules Q2 2026 Earnings Conference Call

Basilea Pharmaceutica ( ($CH:BSLN) ) just unveiled an announcement. The U.S. Biomedical Advanced Research and Development Authority has released an...

BARDA injects $30 million into Basilea’s phase 3 antifungal program

Soluna Holdings ( ($SLNH) ) has issued an announcement. On July 9, 2026, Soluna Holdings, Inc. adjusted the compensation package for Chief Executiv...

Soluna Holdings Boosts CEO Pay, Ties to Performance

In a report released today, from Ord Minnett maintained a Hold rating on CSL, with a price target of A$123.30. In addition to Ord Minnett, CSL also...

Ord Minnett Reaffirms Their Hold Rating on CSL (CMXHF)

In a report released on July 19, from Guotai Haitong maintained a Buy rating on Stella International Holdings Limited, with a price target of HK$18...

Guotai Haitong Reaffirms Their Buy Rating on Stella International Holdings Limited (SLNLF)

Morgan Stanley analyst maintained a Hold rating on Stella International Holdings Limited on July 17 and set a price target of HK$14.50. The company...

Stella International Holdings Limited (SLNLF) Receives a Hold from Morgan Stanley

Southland stock was up on Friday after the company announced new construction contracts.


Why Is Penny Stock Southland (SLND) Up Today?

Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Arhaus (ARHS) and Stella International Hold...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLN	$13.72	-1.79%	823.93K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLN	$13.72	-1.8%	823.93K
3
4
5
6

SLN

Get Silence Therapeutics plc Data in Excel

Get Silence Therapeutics plc Data in Excel